智飞生物上半年亏6亿总股本7.72%质押 去年净利降7成

Core Points - The company Zhifei Biological (300122.SZ) reported a significant decline in revenue and profit for the first half of 2025, with a revenue of 4.919 billion yuan, a year-on-year decrease of 73.06% [1] - The net profit attributable to shareholders was -597 million yuan, compared to 2.234 billion yuan in the same period last year, indicating a substantial loss [1] - The cash flow from operating activities showed improvement, with a net cash flow of 1.564 billion yuan, compared to -307 million yuan in the previous year [1] Financial Performance Summary - For the year 2024, Zhifei Biological reported a revenue of 26.070 billion yuan, down 50.74% year-on-year [1] - The net profit attributable to shareholders for 2024 was 2.018 billion yuan, a decrease of 74.99% compared to the previous year [1] - The net profit after deducting non-recurring gains and losses was 1.991 billion yuan, down 74.84% year-on-year [1] - The cash flow from operating activities for 2024 was -4.414 billion yuan, a decline of 149.06% year-on-year [1] Shareholding Structure - As of June 30, 2025, the controlling shareholder and actual controller of Zhifei Biological is Jiang Rensheng, who holds 1,159,573,500 shares, representing 48.44% of the total shares [2] - Jiang Rensheng has pledged 184,700,000 shares, which accounts for 15.93% of his holdings and 7.72% of the total shares of Zhifei Biological [2]